Life Science REIT Provides Portfolio Valuation and NTA Update
Why we think this is neutral
The RNS announcement provides an update on the company's portfolio valuation and net tangible asset (NTA) position, but does not contain any of the mandatory news types such as contract news, order news, trading update, or annual results. As such, the sentiment is considered neutral.
Key Points
- Portfolio valuation declined 7.8% to £332.6 million as of 31 December 2025
- EPRA NTA declined 13.0% to £201.8 million, or 57.7 pence per share
- Declines driven by outward yield shift and ongoing vacancy issues at certain assets
Summary
Life Science REIT plc has announced that its portfolio valuation as at 31 December 2025 was £332.6 million, representing a 7.8% decline from the 30 June 2025 portfolio valuation of £360.6 million. The unaudited 31 December 2025 EPRA NTA was £201.8 million, or 57.7 pence per share, representing a 13.0% decline from the 30 June 2025 EPRA NTA of £232.1 million, or 66.3 pence per share. The fall in value is predominantly due to outward yield shift across the portfolio and ongoing vacancy issues at certain assets.